Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tixocortol Pivalate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 8/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 10/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.60 |
| ▸ | PGR | P06401 | 5/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.60 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.56 |
| ▸ | SHBG | P04278 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | AR | P10275 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triamcinolone SCHEMBL593313 | 0.93 | HIF1A (0.68) | HIF1AHSD17B10CYP3A4NR3C1PGR | |
| Dexamethasone SCHEMBL322760 | 0.88 | HIF1A (0.69) | HIF1AHSD17B10CYP3A4NR3C1PGR | |
| Betamethasone SCHEMBL28086533 | 0.86 | HIF1A (0.66) | HIF1AHSD17B10CYP3A4NR3C1PGR | |
| Triamcinolone SCHEMBL5151654 | 0.84 | HIF1A (0.72) | HIF1AHSD17B10CYP3A4NR3C1PGR | |
| Betamethasone Dipropionate SCHEMBL22463713 | 0.84 | NR3C1 (0.64) | HIF1ACYP3A4NR3C1PGRLMNA | |
| Tixocortol Pivalate SCHEMBL16516121 | 0.83 | NR3C1 (0.72) | HIF1AHSD17B10CYP3A4NR3C1PGR | |
| Triamcinolone SCHEMBL9837854 | 0.82 | HIF1A (0.66) | HIF1AHSD17B10CYP3A4NR3C1PGR | |
| Hydrocortisone Phosphoric Acid SCHEMBL8190634 | 0.82 | HIF1A (0.66) | HIF1AHSD17B10CYP3A4NR3C1PGR | |
| Tixocortol Pivalate SCHEMBL6827 | 0.81 | NR3C1 (0.75) | HIF1AHSD17B10CYP3A4NR3C1PGR | |
| Tixocortol Pivalate SCHEMBL5484132 | 0.81 | NR3C1 (0.75) | HIF1AHSD17B10CYP3A4NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9675696-B2 | Method and use for increasing efficacy of anti-adhesive compositions in controlling inflammation and pain | WARSAW ORTHOPEDIC, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| EP-2104505-B1 | METHOD AND USE FOR INCREASING EFFICACY OF ANTI-ADHESIVE COMPOSITIONS IN CONTROLLING INFLAMMATION AND PAIN | WARSAW ORTHOPEDIC INC (US) | 2014-05-21 | — | — | EP | disclosed |
| EP-2465513-A2 | Method and use for increasing efficacy of anti-adhesive compositions in controlling inflammation and pain | Warsaw Orthopedic, Inc. (US) | 2012-06-20 | — | — | EP | disclosed |
| EP-2104505-A2 | METHOD AND USE FOR INCREASING EFFICACY OF ANTI-ADHESIVE COMPOSITIONS IN CONTROLLING INFLAMMATION AND PAIN | Warsaw Orthopedic, Inc. (US) | 2009-09-30 | — | — | EP | disclosed |
| WO-2008063943-A2 | METHOD AND USE FOR INCREASING EFFICACY OF ANTI-ADHESIVE COMPOSITIONS IN CONTROLLING INFLAMMATION AND PAIN | WARSAW ORTHOPEDIC, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20080112921-A1 | Method and use for increasing efficacy of anti-adhesive compositions in controlling inflammation and pain | WARSAW ORTHOPEDIC, INC. | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080112921-A1 | Method and use for increasing efficacy of anti-adhesive compositions in controlling inflammation and pain | ICAM1, MMP8, VCAM1 | NR3C1 3228/4885HIF1A 2480/4885HSD17B10 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.